Telmisartan+HCTZ, Hypertension - Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00659607

Locations


Korea, Republic of
	Boehringer Ingelheim
	Busan, Korea, Republic of
	Boehringer Ingelheim
	Seoul, Korea, Republic of
	Boehringer Ingelheim
	Gyeonggido, Korea, Republic of
	Boehringer Ingelheim
	Gwangju, Korea, Republic of
	Boehringer Ingelheim
	Daegu, Korea, Republic of
	Boehringer Ingelheim
	Daejeon, Korea, Republic of
	Boehringer Ingelheim
	Chungnam, Korea, Republic of
	Boehringer Ingelheim
	Incheon, Korea, Republic of
	Boehringer Ingelheim
	Jeju, Korea, Republic of
	Boehringer Ingelheim
	Jeonnam, Korea, Republic of
	Boehringer Ingelheim
	Jeonbuk, Korea, Republic of
	Boehringer Ingelheim
	Ulsan, Korea, Republic of
	Boehringer Ingelheim
	Gangwondo, Korea, Republic of

Sponsors and Collaborators

Boehringer Ingelheim Pharmaceuticals

Investigators


Study Chair:	Boehringer Ingelheim Study Coordinator	B.I. Korea Ltd.